ES2179049T3 - Oxepano-isomeros de rapamicina utiles como agentes inmunosupresores. - Google Patents

Oxepano-isomeros de rapamicina utiles como agentes inmunosupresores.

Info

Publication number
ES2179049T3
ES2179049T3 ES93300207T ES93300207T ES2179049T3 ES 2179049 T3 ES2179049 T3 ES 2179049T3 ES 93300207 T ES93300207 T ES 93300207T ES 93300207 T ES93300207 T ES 93300207T ES 2179049 T3 ES2179049 T3 ES 2179049T3
Authority
ES
Spain
Prior art keywords
useful
rapamicina
oxepano
isomeros
immunosuppressing agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93300207T
Other languages
English (en)
Inventor
Philip Floyd Hughes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25235357&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2179049(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth LLC filed Critical Wyeth LLC
Application granted granted Critical
Publication of ES2179049T3 publication Critical patent/ES2179049T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCION SE REFIERE A UN DERIVADO DE RAPAMICINA DE FORMULA GENERAL Y DERIVADOS FUNCIONALES DEL MISMO QUE, EN VIRTUD DE SU ACTIVIDAD INMUNOSUPRESORA, SON DE UTILIDAD EN EL TRATAMIENTO DE ELEMENTOS DE RECHAZO DE TRASPLANTES PARA EVITAR ENFERMEDADES DE INJERTOS, TRASTORNOS DE AUTOINMUNIDAD Y ENFERMEDADES DE INFLAMACION.
ES93300207T 1992-01-16 1993-01-14 Oxepano-isomeros de rapamicina utiles como agentes inmunosupresores. Expired - Lifetime ES2179049T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/822,171 US5221740A (en) 1992-01-16 1992-01-16 Oxepane isomers of rapamycin useful as immunosuppressive agents

Publications (1)

Publication Number Publication Date
ES2179049T3 true ES2179049T3 (es) 2003-01-16

Family

ID=25235357

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93300207T Expired - Lifetime ES2179049T3 (es) 1992-01-16 1993-01-14 Oxepano-isomeros de rapamicina utiles como agentes inmunosupresores.

Country Status (9)

Country Link
US (2) US5221740A (es)
EP (1) EP0552031B1 (es)
JP (3) JP3108557B2 (es)
AT (1) ATE219084T1 (es)
CA (1) CA2086643C (es)
DE (1) DE69332005T2 (es)
DK (1) DK0552031T3 (es)
ES (1) ES2179049T3 (es)
PT (1) PT552031E (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH686761A5 (de) 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
DE69535871D1 (de) 1994-08-24 2008-12-04 Canon Kk Tintenbehälter für Tintenstrahldrucker, Halter für den Behälter, Druckwagen für den Halter und Tintenstrahldrucker
GB9713730D0 (en) 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
US7807211B2 (en) 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
US6790228B2 (en) * 1999-12-23 2004-09-14 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US20040137066A1 (en) * 2001-11-26 2004-07-15 Swaminathan Jayaraman Rationally designed therapeutic intravascular implant coating
US6641611B2 (en) 2001-11-26 2003-11-04 Swaminathan Jayaraman Therapeutic coating for an intravascular implant
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
WO2006041942A2 (en) * 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
US8313763B2 (en) * 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
AU2006221024A1 (en) * 2005-03-07 2006-09-14 Wyeth Oxepane isomer of 42-O-(2-hydroxy)ethyl-rapamycin
US7622477B2 (en) * 2006-02-28 2009-11-24 Cordis Corporation Isomers and 42-epimers of rapamycin alkyl ether analogs, methods of making and using the same
US20070203168A1 (en) * 2006-02-28 2007-08-30 Zhao Jonathon Z Isomers of rapamycin and 42-Epi-rapamycin, methods of making and using the same
US20070203171A1 (en) * 2006-02-28 2007-08-30 Zhao Jonathon Z Combination of rapamycin and its tetrazole isomers and epimers, methods of making and using the same
PL2080620T3 (pl) 2006-11-06 2011-10-31 Seiko Epson Corp Zbiornik cieczy, uchwyt zbiorników oraz urządzenie zużywające ciecz
JP4946751B2 (ja) 2006-11-06 2012-06-06 セイコーエプソン株式会社 容器ホルダ、液体消費装置及び液体収容容器
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
JP2008305262A (ja) * 2007-06-08 2008-12-18 Konica Minolta Business Technologies Inc サーバ及びシンクライアント環境でのプリンタ紹介方法
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
PT2365802T (pt) 2008-11-11 2017-11-14 Univ Texas Microcápsulas de rapamicina e utilização para o tratamento de cancro
US20170079962A1 (en) 2009-11-11 2017-03-23 Rapamycin Holdings, Llc Oral Rapamycin Preparation and Use for Stomatitus
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
MX342590B (es) 2010-04-27 2016-10-05 Roche Glycart Ag Terapia de combinacion de un anticuerpo cd20 afucosilado con un inhibidor mtor.
JP2014519813A (ja) 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ，エルエルシー 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
WO2013013708A1 (en) 2011-07-26 2013-01-31 Fundació Institut D'investigació Biomèdica De Bellvitge Treatment of acute rejection in renal transplant
US9750728B2 (en) 2012-09-29 2017-09-05 Targeted Therapeutics, Llc Method and pharmaceutical composition for inhibiting PI3K/AKT/mTOR signaling pathway
CN103705925B (zh) 2012-09-29 2018-03-30 段磊 抑制PI3K/AKT/mTOR信号通路的药物组合
WO2014059295A1 (en) 2012-10-12 2014-04-17 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors to treat vascular cognitive impairment
WO2014160328A1 (en) 2013-03-13 2014-10-02 The Board Of Regents Of The University Of Texas System Mtor inhibitors for prevention of intestinal polyp growth
CN103739616B (zh) * 2013-12-27 2015-12-30 福建省微生物研究所 含噻唑基雷帕霉素类衍生物及其应用
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
AU2014373683B2 (en) 2013-12-31 2020-05-07 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
WO2015149001A1 (en) 2014-03-27 2015-10-01 The Brigham And Women's Hospital, Inc. Metabolically-activated drug conjugates to overcome resistance in cancer therapy
CN106659758A (zh) 2014-06-02 2017-05-10 儿童医疗中心有限公司 用于免疫调节的组合物和方法
IL303660A (en) 2017-05-02 2023-08-01 Revolution Medicines Inc Rapamycin analogs as mtor inhibitors
EP3848065B1 (en) 2017-05-15 2023-07-26 C. R. Bard, Inc. Medical device with drug-eluting coating and intermediate layer
CA3098698A1 (en) 2018-05-01 2019-11-07 Revolution Medicines, Inc. C26-linked rapamycin analogs as mtor inhibitors
CN118978535A (zh) 2018-05-01 2024-11-19 锐新医药公司 作为mTOR抑制剂的C40-、C28-及C-32连接的雷帕霉素类似物
JP7262581B2 (ja) 2018-11-14 2023-04-21 ルトニックス，インコーポレーテッド 改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス
JP7487228B2 (ja) 2019-04-08 2024-05-20 バード・ペリフェラル・バスキュラー・インコーポレーテッド 改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス
JP2024529341A (ja) 2021-07-15 2024-08-06 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 粒子が付着している細胞に関連する組成物および方法
JP2025522296A (ja) 2022-05-25 2025-07-15 レヴォリューション・メディスンズ，インコーポレイテッド ｍＴＯＲ阻害剤によりがんを処置する方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
GB2246350A (en) * 1990-07-23 1992-01-29 Fujisawa Pharmaceutical Co Tricyclo compounds
US5091389A (en) * 1991-04-23 1992-02-25 Merck & Co., Inc. Lipophilic macrolide useful as an immunosuppressant

Also Published As

Publication number Publication date
EP0552031A1 (en) 1993-07-21
CA2086643C (en) 2002-11-26
ATE219084T1 (de) 2002-06-15
DE69332005D1 (de) 2002-07-18
JP3108557B2 (ja) 2000-11-13
JP2003180385A (ja) 2003-07-02
PT552031E (pt) 2002-09-30
JP2004313196A (ja) 2004-11-11
CA2086643A1 (en) 1993-07-17
DE69332005T2 (de) 2002-11-14
EP0552031B1 (en) 2002-06-12
US5344833A (en) 1994-09-06
US5221740A (en) 1993-06-22
JPH06312990A (ja) 1994-11-08
DK0552031T3 (da) 2002-09-23

Similar Documents

Publication Publication Date Title
PT552031E (pt) Isomeros oxepano da rapamicina como agentes imunossupressores
DE69408678D1 (de) C-22 ringstabilisierte rapamycin derivate
DE69724811D1 (de) Pentafluorobenzensulfonamide und analoge
ATE214379T1 (de) Cyclodepsipeptide
TR199801919T2 (xx) Rapamisin t�revlerinin damar hastal�klar� ve yabanc� doku naklinde kullan�m�.
PT920421E (pt) Derivados de isoxazolina uteis como agentes antimicrobianos
ES2119912T3 (es) Nuevos aminometilenpeptidos como inmunosupresores.
ES2116471T3 (es) Arilcarbonil y alcoxicarbonil carbamatos de rapamicina como agentes inmunosupresores y antifungicos.
MX9306271A (es) Carbamatos de rapamicina y composicion farmaceutica que los incluye.
DE69711996D1 (de) 2-Aminobenzazepin-Derivate und ihre Verwendung für die Behandlung von Immunosuppression
ATE211472T1 (de) Kondensierte pyrrolocarbazole
DE69302249D1 (de) Prolinderivat von Rapamycin, seine Herstellung und Verwendung
AR029214A1 (es) Compuestos inhibidores de fosfodiesterasa - 4: 8 - arilquinolinas sustituidas, composiciones farmaceuticas, metodo de tratamiento que las utiliza
ES2136887T3 (es) Derivados antifungicos de sordaridina.
BR9712081A (pt) Novos derivados de pept¡deos tendo res¡duo tiazolil-alanina
ATE172985T1 (de) Sulfonamidaminomethylenderivate als immunsuppressiva
MX9606494A (es) Compuestos organicos.
FI945164A7 (fi) Biologisesti aktiivisesti ureidojohdannaiset, jotka ovat käyttökelpoisia antimetastaattisina aineina
MX9304626A (es) Derivados heterociclicos utiles en el tratamiento de enfermedades cardiovasculares.
FI963222A0 (fi) 6-substituoitu 4-amino-mykofenolihappo ja sen johdannaiset, joilla on immunosuppressiivista aktiivisuutta
DE69637641D1 (de) Auf rapamycin basierende regulation biologischer vorgänge
DK0551844T3 (da) Svovlholdige galdesyrederivater
DE69611148D1 (de) Pyrrolo(4,3,2-de)chinolin-Derivat
ECSP972236A (es) Derivados de 6,6- heterobiciclicos sustituidos
ES2167569T3 (es) Uso de imidazo(1,5-a)quinolonas como agentes neuroprotectores.